- Clinical Trials
- April 2024
- 550 Pages
Global
From €4804EUR$5,000USD£4,107GBP
- Report
- June 2022
- 117 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- February 2022
- 308 Pages
Global
From €9128EUR$9,500USD£7,804GBP
- Report
- June 2021
- 50 Pages
China
From €2498EUR$2,600USD£2,136GBP
- Report
- February 2024
- 91 Pages
Global
From €3500EUR$3,902USD£3,097GBP
- Report
- May 2024
- 50 Pages
Global
From €2546EUR$2,650USD£2,177GBP
- Report
- July 2023
- 199 Pages
China
From €3843EUR$4,000USD£3,286GBP
- Report
- July 2023
- 98 Pages
China
From €1730EUR$1,800USD£1,479GBP
- Report
- August 2020
- 113 Pages
Global
From €4324EUR$4,500USD£3,697GBP
Oxaliplatin is a chemotherapy drug used to treat colon cancer. It is a platinum-based drug, meaning it works by interfering with the growth of cancer cells. Oxaliplatin is often used in combination with other drugs, such as 5-fluorouracil and leucovorin, to create a more effective treatment. It is typically administered intravenously, and is used to treat both early and advanced stages of colon cancer.
Oxaliplatin is a relatively new drug, having been approved by the FDA in 2002. It has become a popular treatment option due to its effectiveness and relatively low side effects. Common side effects include nausea, vomiting, and fatigue.
The Oxaliplatin market is highly competitive, with many companies offering their own versions of the drug. Some of the major players in the market include Sanofi, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more
